ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2013 Dec 4

PMID 24296758

Citations 69

Authors

Dara L Aisner

Teresa T Nguyen

Diego D Paskulin

Anh T Le

Jerry Haney

Nathan Schulte

Fiona Chionh

Jenny Hardingham

John Mariadason

Niall Tebbutt

Robert C Doebele

Andrew J Weickhardt

Marileila Varella-Garcia

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Activated anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases, through gene fusions, have been found in lung adenocarcinomas and are highly sensitive to selective kinase inhibitors. This study aimed at identifying the presence of these rearrangements in human colorectal adenocarcinoma specimens using a 4-target, 4-color break-apart FISH assay to simultaneously determine the genomic status of ALK and ROS1. Among the clinical colorectal cancer specimens analyzed, rearrangement-positive cases for both ALK and ROS1 were observed. The fusion partner for ALK was identified as EML4 and the fusion partner for one of the ROS1-positive cases was SLC34A2, the partner for the other ROS1-positive case remains to be identified. A small fraction of specimens presented duplicated or clustered copies of native ALK and ROS1. In addition, rearrangements were detected in samples that also harbored KRAS and BRAF mutations in two of the three cases. Interestingly, the ALK-positive specimen displayed marked intratumoral heterogeneity and rearrangement was also identified in regions of high-grade dysplasia. Despite the additional oncogenic events and tumor heterogeneity observed, elucidation of the first cases of ROS1 rearrangements and confirmation of ALK rearrangements support further evaluation of these genomic fusions as potential therapeutic targets in colorectal cancer.

Implications: ROS1 and ALK fusions occur in colorectal cancer and may have substantial impact in therapy selection.

Citing Articles

Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer.

Kou F, Li J, Wang Z, Xu T, Qian J, Zhang E Gastroenterol Rep (Oxf). 2024; 12:goae092.

PMID: 39391592 PMC: 11464618. DOI: 10.1093/gastro/goae092.

Clinicopathological features, prognostic factor analysis, and survival nomogram of patients with double primary cancers involving lung cancer.

Hao Y, Zhang X, Cui G, Qi X, Jiang Z, Yu L Cancer Med. 2024; 13(10):e7296.

PMID: 38770671 PMC: 11106682. DOI: 10.1002/cam4.7296.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review.

Hu T, Zhan J, Li L, He Y, Lin Y, Wang J Oncologist. 2024; 30(1).

PMID: 38381603 PMC: 11783296. DOI: 10.1093/oncolo/oyae020.

Receptor tyrosine kinases: biological functions and anticancer targeted therapy.

Zhang N, Li Y MedComm (2020). 2023; 4(6):e446.

PMID: 38077251 PMC: 10701465. DOI: 10.1002/mco2.446.

Routine Clinically Detected Increased Transcripts Are Related With Expression by Immunohistochemistry and Associated With Mutations in Lung Adenocarcinoma.

Grenier K, Riviere J, Bencheikh B, Corredor A, Shieh B, Wang H JTO Clin Res Rep. 2023; 4(7):100530.

PMID: 37415647 PMC: 10320302. DOI: 10.1016/j.jtocrr.2023.100530.

References

Lin E, Li L, Guan Y, Soriano R, Rivers C, Mohan S . Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009; 7(9):1466-76. DOI: 10.1158/1541-7786.MCR-08-0522. View

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

Gu T, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V . Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011; 6(1):e15640. PMC: 3017127. DOI: 10.1371/journal.pone.0015640. View

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M . Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18(3):382-4. PMC: 3916180. DOI: 10.1038/nm.2673. View

Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E . Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17(3):889-97. DOI: 10.1245/s10434-009-0808-7. View

Alrifai D, Popat S, Ahmed M, Gonzalez D, Nicholson A, du Parcq J . A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer. 2013; 80(3):339-40. DOI: 10.1016/j.lungcan.2013.02.002. View

Price T, Hardingham J, Lee C, Weickhardt A, Townsend A, Wrin J . Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol. 2011; 29(19):2675-82. DOI: 10.1200/JCO.2010.34.5520. View

Bavi P, Jehan Z, Bu R, Prabhakaran S, Al-Sanea N, Al-Dayel F . ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer. 2013; 109(10):2735-43. PMC: 3833224. DOI: 10.1038/bjc.2013.641. View

10.

Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M . EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer. 2008; 98(9):1536-9. PMC: 2391097. DOI: 10.1038/sj.bjc.6604341. View

11.

Tebbutt N, Wilson K, Gebski V, Cummins M, Zannino D, Van Hazel G . Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010; 28(19):3191-8. DOI: 10.1200/JCO.2009.27.7723. View

12.

Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R . KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012; 7(2):e31323. PMC: 3275577. DOI: 10.1371/journal.pone.0031323. View

13.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

14.

Koivunen J, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes A . EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14(13):4275-83. PMC: 3025451. DOI: 10.1158/1078-0432.CCR-08-0168. View

15.

Karkouche R, Bachet J, Sandrini J, Mitry E, Penna C, Cote J . Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012; 24(12):1430-7. DOI: 10.1097/MEG.0b013e3283583c87. View

16.

An S, Chen Z, Su J, Zhang X, Zhong W, Yang J . Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012; 7(6):e40109. PMC: 3387024. DOI: 10.1371/journal.pone.0040109. View

17.

Boland J, Jang J, Li J, Lee A, Wampfler J, Erickson-Johnson M . MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol. 2013; 8(5):574-81. DOI: 10.1097/JTO.0b013e318287c395. View

18.

Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K . Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum. 2011; 54(9):1170-8. DOI: 10.1097/DCR.0b013e31821d37a3. View

19.

Davies K, Doebele R . Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013; 19(15):4040-5. PMC: 3732549. DOI: 10.1158/1078-0432.CCR-12-2851. View

20.

Davies K, Le A, Theodoro M, Skokan M, Aisner D, Berge E . Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012; 18(17):4570-9. PMC: 3703205. DOI: 10.1158/1078-0432.CCR-12-0550. View